Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated